A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma

PHASE2RecruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

July 19, 2022

Primary Completion Date

March 31, 2025

Study Completion Date

December 31, 2025

Conditions

Asthma

Interventions

DRUG

GR1802 injection

GR1802 will be administered SC.

DRUG

GR1802 injection

GR1802 will be administered SC.

OTHER

Placebo

The placebo will be administered SC.

Trial Locations (1)

RECRUITING

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors

lead

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

INDUSTRY